Chinese e-commerce giants make expensive bets on fast deliveries
Investors will be dissecting the strategy when JD.com reports its quarterly earnings on Tuesday and Alibaba on Thursday, as finding new avenues for growth has proven challenging for China's largest online retailers.
Their market penetration is already high and prices for goods are under pressure due to a consumer slowdown driven by concerns about employment and wages as well as a prolonged property market downturn.
The new turf war focused on speed is coming at a high cost in the short term as the e-commerce giants look to entice consumers with hefty discounts.
JD.com's JD Takeaway and Alibaba's food delivery app Ele.me last month each pledged 10 billion yuan (S$1.8 billion) in subsidies. JD Takeaway said it would invest the sum over a year, while Ele.me did not disclose the timeframe.
'The competition is so intense, there's not a lot of incremental growth opportunities, so everybody is moving into everybody else's territories and instant retail is the latest example of that,' said Jason Yu, general manager at CTR Market Research.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
China's food delivery market leader Meituan has moved to grow its business by expanding its instashopping platform, which delivers non-food goods within 30 minutes and JD.com announced its entry into food delivery in February.
'In the past people would go to JD.com to buy a mobile phone and they would deliver to you in the same day, then suddenly they could go to Meituan and have the new Apple iPhone delivered within 30 minutes. That posed a direct threat to JD.com and they moved into food delivery in response,' Yu said.
At the end of April, Alibaba expanded its instant shopping portal on its domestic e-commerce app Taobao. That gave users access to restaurants, coffee shops and bubble tea chains available on Alibaba's Ele.me - China's second-largest food delivery player behind Meituan - plus many other categories including pet food and apparel.
Alibaba, JD.com and Meituan did not respond to requests for comment.
Subsidised spending on instant retail from Alibaba and JD.com is being welcomed by cost-conscious consumers.
Users on JD Takeaway currently enjoy discounts of up to 20 yuan, or US$2.77, per day for deliveries from restaurants including McDonald's, Haidilao and Burger King. On Taobao's instant shopping portal, consumers can receive a discount of 11 yuan on a bill of at least 15 yuan.
Liu Qi, 24, a small business owner in Tianjin, said he was pleased when he recently bought a coconut latte on JD Takeaway for only 5.9 yuan.
'I asked the deliveryman and he said he makes 4 yuan per delivery, so essentially, JD.com bought me a cup of coffee and delivered it to my door,' Liu said.
He was even more surprised days later when he bought a coffee on Taobao's instant shopping portal for only 3.9 yuan. 'It was 2 yuan cheaper than JD.com!' he said.
War chests
While subsidising consumer discounts for instant retail is expensive, China's e-commerce giants have significant cash reserves. As of Dec 31, Alibaba, JD.com and Meituan had net cash positions of 400 billion, 144 billion and 110 billion yuan respectively, according to Morningstar analysts.
And despite the low margins inherent in the business, a renewed focus on instant retail made sense for JD.com and Alibaba in part because both firms have armies of couriers already at their disposal, analysts said.
That means there is no need for an expensive build-out of delivery infrastructure as would be required for other potential entrants like Temu-owner PDD Holdings.
Beijing-based independent industry analyst Liu Xingliang said Alibaba and JD.com were leveraging high-frequency demand for food, coffee and bubble tea to boost lower-frequency demand for clothing, electronics and other higher-margin purchases - betting that if consumers open their apps more often, they might buy more overall.
For JD.com, the expansion into instant retail was particularly important given its traditional e-commerce business appeared to have hit a ceiling, he said.
'It must try to gain market share in new business areas.' REUTERS

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNA
43 minutes ago
- CNA
Starlink back up after brief outage in US, Downdetector shows
Elon Musk's Starlink was back up for users in the U.S. after a brief outage on Monday, according to tracking website The outage eased to over 2,800 users reporting issues with the service as of 2:13 p.m. ET, from its peak of over 43,000 incidents, according to the website, which tracks outages by collating status reports from multiple sources. Downdetector's numbers are based on user-submitted reports. The actual number of affected users may vary.

Straits Times
2 hours ago
- Straits Times
Novo Nordisk offers Ozempic at $640 per month to eligible US cash-paying customers
Sign up now: Get ST's newsletters delivered to your inbox GoodRx will sell Wegovy and Ozempic at US$499 monthly to eligible self-paying patients. BAGSVAERD - Novo Nordisk said on Aug 18 it was offering its diabetes drug Ozempic for US$499 (S$640.83) per month to eligible cash-paying patients with type 2 diabetes in the US via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms. US-listed shares of the Danish drugmaker were up 5.3 per cent, while shares of GoodRx rose 34.2 per cent. Novo and rival Eli Lilly have expanded into direct-to-consumer sales for the highly effective and sought-after medicines, in part due to competition from online telehealth companies and pharmacies that sell cheaper compounded versions. Novo already sells Wegovy, the weight-loss version of Ozempic, through its NovoCare pharmacy for US$499. The latest offer is aimed at patients who do not have insurance coverage. Its shares were also trading higher after Wegovy secured US FDA approval for the liver disease metabolic dysfunction-associated steatohepatitis, or MASH, on Aug 15. GoodRx will sell Wegovy and Ozempic at US$499 monthly to eligible self-paying patients. A spokesperson for Novo said it expected Ozempic cash sales to account for about 10 per cent of total prescriptions - the same level of market penetration the company has experienced with Wegovy. Top stories Swipe. Select. Stay informed. Singapore Jobs, infrastructure and homes at the core of Singapore's resilience: Economists Business New online tools by SkillsFuture Singapore help companies plan and curate staff training Life Chinese EV brand Nio to be launched in Singapore in first quarter of 2026 Asia 2 firefighters die in building fire at Osaka's Dotonbori tourist district Singapore Driver hurt after car turns turtle in Upper Thomson accident Sport National tennis player Shaheed Alam serves up charity event to benefit migrant workers Life New Blackpink album scheduled for November, YG Entertainment confirms Singapore Jail for driver of 11-tonne garbage truck that ran over cyclist in Woodlands Novo said earlier in August it expects continued competition from copycat versions and rising pressure from Lilly. List prices for each drug in the United States are about US$1,000 per month or more, but insured patients pay far less. Eli Lilly offers single-dose vials of its weight-loss drug Zepbound on its website, LillyDirect, for US$499 per month or less, regardless of insurance status. Lilly does not sell its diabetes drug Mounjaro on LillyDirect. Novo said the new offer for Ozempic was part of ongoing efforts to explore new collaborations and approaches towards improving access to authentic semaglutide medicines. In April, it said it was working with telehealth firms Ro and LifeMD to sell Wegovy to expand access to cash-paying patients. REUTERS

Straits Times
3 hours ago
- Straits Times
Hong Kong arrests 2 over suspected S$8.6m water scam
Sign up now: Get ST's newsletters delivered to your inbox Officers seized around 2,600 bottles of water in a warehouse along with documents and electronic devices. HONG KONG - Hong Kong police said on Aug 18 they have arrested two people over a suspected scam involving a water supplier that may have cheated the government in a contract worth nearly US$7 million (S$8.99 million). A company named Xin Ding Xin won a deal in June to provide 1.88 million bottles of water which would go into dispensers in some government offices – the first time such a contract went to a Chinese brand, according to local media. But police said the firm was found to have relied on false documents during the tender process, claiming to source its water from another mainland Chinese supplier when in fact they had no business ties. Officers arrested a 61-year-old man and a 57-year-old woman for fraud on Aug 17, seizing around 2,600 bottles of water in a warehouse along with documents and electronic devices. The arrests have prompted water-cooler discussions across the Chinese finance hub on how bureaucrats missed the telltale signs of a scam when awarding a 36-month contract worth HK$52.9 million (S$8.6 million). Payment for the delivered batches has not yet been settled, according to police. The Government Logistics Department said on Aug 18 that it terminated its bottled water supply contract with Xin Ding Xin, as well as 'three other contracts for supply of chemicals which were affiliated with XDX's owner'. Christopher Hui, Hong Kong's secretary for financial services and the treasury, set up a dedicated task force following an urgent meeting on Aug 17. Hui also ordered 'remedial actions' and invited the Audit Commission to review the tender exercise. 'The incident has brought up concerns among government colleagues and drawn extensive attention from the public,' he said in a press release. Aside from the two arrests on Aug 17, one mainland Chinese man remains at large, police said. AFP